Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: A UNOS Region 6 pooled analysis

Clinical Transplantation

Volumn 27, Issue 1, 2013, Pages

  Wong, Linda L ^a   Naugler, Willscott E ^b   Schwartz, Jonathan ^b   Scott, David L ^b,c   Bhattacharya, Renuka ^d   Reyes, Jorge ^d   Orloff, Susan L ^b,c  

^a Hawaii Medical Center East   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Alpha fetoprotein; Chemoembolization; Hepatocellular cancer; Liver transplant; Locoregional therapy

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADOLESCENT; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84873089915     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12056     Document Type: Article

References (40)

1. World Health Organization at http://who.int (accessed September 1, 2010).
2. National Cancer Institute, SEER data at http://cancer.gov/statistics (accessed October 1, 2010).
3. Mazzaferro V, Regallia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693.
4. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007: 7: 2587.
5. Yao FY, Kerlan RK Jr, Hirose R et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008: 48: 819.
6. Shi XJ, Jin X, Wang MQ et al. Outcomes of loco-regional therapy for down-staging of hepatocellular carcinomaprior to liver transplantation. Hepatobiliary Pancreat Dis Int 2011: 10: 143.
7. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009: 10: 35.
8. Parfitt JR, Marotta P, Alghamdi M et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007: 13: 543.
9. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010: 16: 925.
10. Mailey B, Artinuyan A, Khalili J et al. Evaluation of absolute serum alpha-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011: 146: 26.
11. Levi DM, Tzakis AG, Martin P et al. Liver transplant for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg 2010: 210: 727.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005: 42: 1208.
13. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989: 64: 1700.
14. Tangkijvanich P, Anukulkarnkusol N, Suwangool P et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000: 31: 302.
15. Huo TI, Huang YH, Lui WY et al. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004: 11: 543.
16. Farinati F, Marino D, De Giorgio M et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006: 101: 524.
17. Reichman TW, Bahramipour P, Barone A, Koneru B. Hepatitis status, Child-Pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg 2005: 9: 638.
18. Xu HX, Lu MD, Xie XY et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol 2005: 60: 1018.
19. Toyoda H, Kumada T, Kaneoka Y et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008: 49: 223.
20. Furihata T, Sawada T, Kita J et al. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology 2008: 55: 1705.
21. Cherqui D, Laurent A, Mocellin N et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009: 250: 738.
22. Tsai MC, Wang JH, Hung CH et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2010: 25: 605.
23. Eguchi S, Takatsuki M, Hidaka M et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg 2010: 34: 1034.
24. Hsieh CB, Chen TW, Chu CM, Chu HC, Yu CP, Chung KP. Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence? World J Gastroenterol 2010: 16: 3049.
25. Nobuoka D, Kato Y, Gotohda N et al. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 2010: 24: 521.
26. Del Gaudio M, Grazi GL, Principe A et al. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterology 2004: 51: 510.
27. Yamashiki N, Gaynor JJ, Kato T et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant 2004: 4: 774.
28. McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford) 2010: 12: 56.
29. Shetty K, Timmins K, Brensinger C et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004: 10: 911.
30. Pérez-Saborido B, de los Galanes SJ, Menéu-Díaz JC et al. Tumor recurrence after liver transplantation for hepatocellular carcinoma recurrence pathway and prognostic factors. Transplant Proc 2007: 39: 2304.
31. Zou WL, Zang YJ, Chen XG, Shen ZY. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation. Hepatobiliary Pancreat Dis Int 2008: 7: 145.
32. Xu X, Ke QH, Shao ZX et al. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci 2009: 54: 385.
33. Lao OB, Weissman J, Perkins JD. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clin Transplant 2009: 23: 874.
34. Han K, Tzimas GN, Barkun JS et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007: 21: 39.
35. Vibert E, Azoulay D, Hoti E et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010: 10: 129.
36. Kondili LA, Lala A, Gunson B et al. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol 2007: 33: 868.
37. Cucchetti A, Piscaglia F, Grigioni AD et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol 2010: 52: 880.
38. Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in liver transplantation. Liver Transpl 2009: 15: 574.
39. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008: 134: 1342.
40. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009: 49: 832.